Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ascaridol in preparing medicine for preventing helicobacter pylori and treating disease caused by helicobacter pylori

An anti-Helicobacter pylori, Helicobacter pylori technology, applied in the direction of anti-tumor drugs, drug combinations, pharmaceutical formulations, etc.

Active Publication Date: 2013-06-05
TIANJIN TASLY PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no reports at home and abroad on the effect of ascaridin on inhibiting Helicobacter pylori and treating peptic ulcer, chronic gastritis and other diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ascaridol in preparing medicine for preventing helicobacter pylori and treating disease caused by helicobacter pylori
  • Application of ascaridol in preparing medicine for preventing helicobacter pylori and treating disease caused by helicobacter pylori
  • Application of ascaridol in preparing medicine for preventing helicobacter pylori and treating disease caused by helicobacter pylori

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] The preparation of embodiment 1 expelling ascarid

[0046] The volatile oil of Nepeta chinensis is collected and separated by normal-phase silica gel (≤100um) column chromatography, and the amount of silica gel used is 5 to 50 times the weight of the volatile oil. Fraction I was obtained by eluting about 3 to 5 times the retention volume with n-hexane as the starting solvent. Then, it was eluted with n-hexane / ethyl acetate gradient and collected step by step. The sequence is n-hexane / ethyl acetate (100:1) elution about 3 to 5 times the retention volume to obtain Fraction II; n-hexane / ethyl acetate (80:1) elution about 3 to 5 times the retention volume to obtain Fraction III. The content of ascaridin in fraction III is more than 90%. figure 1 shows the extraction of ascaridin in CDCl 3 middle 1 H NMR, the structure of ascaridin extracted from spectrum analysis is correct. figure 2 The HPLC profile of the ascaridin extracted sample is shown. figure 2 Shown is the...

Embodiment 2

[0047] The preparation of embodiment 2 ascarid

[0048] The volatile oil of Nepeta chinensis is collected and separated by normal-phase silica gel (≤100um) column chromatography, and the amount of silica gel used is 5 to 50 times the weight of the volatile oil. Fraction I was obtained by eluting about 5 times the retention volume with petroleum ether (boiling range 30-60° C.) as the starting solvent. Then, it was eluted with petroleum ether / ethyl acetate gradient and collected step by step. The sequence is about 5 times the retention volume of petroleum ether / ethyl acetate (100:1) to obtain fraction II; petroleum ether / ethyl acetate (80:1) elution of about 5 times the retention volume to obtain fraction III. The content of ascaridin in fraction III is more than 90%.

Embodiment 3

[0049] The preparation of embodiment 3 expelling ascarid

[0050] First fully soak the normal-phase silica gel (≤100um) with 2% to 2.5% silver nitrate solution, and then dry it in the dark and shade for later use. The volatile oil of Nepeta chinensis is taken from the soil, and the above-mentioned silver nitrate silica gel is used for column chromatography separation, and the amount of silica gel used is 5 to 50 times the weight of the volatile oil. After elution with n-hexane as the starting solvent for about 3 to 5 times the retention volume, and then gradient elution with n-hexane / ethyl acetate, the samples were collected step by step. The sequence is about 3 to 5 times the retention volume of n-hexane / ethyl acetate (100:1) to obtain fraction I; n-hexane / ethyl acetate (80:1) about 3 to 5 times the retention volume to obtain Fraction II. The content of ascaridin in fraction II is more than 90%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of ascaridol in preparing medicine for preventing helicobacter pylori.

Description

technical field [0001] The invention relates to the application of ascaridin in the preparation of medicines against Helicobacter pylori. Background technique [0002] Helicobacter pylori (Helicobacter pylori) is a Gram-negative bacterium with unipolar, multi-flagellate, blunt-rounded ends, and helical bends. Helicobacter pylori usually parasitizes in the mucus layer of human gastric alveoli, and relies on the ammonia produced by its urease decomposition to neutralize gastric acid, thereby colonizing the stomach. Two toxins CagA and VacA secreted by Helicobacter pylori, CagA can activate the protein NFAT related to cell proliferation, promote abnormal cell proliferation, and cause a series of inflammatory reactions, leading to chronic inflammation and ulcers of gastric mucosa. In 1982, Warren and Marshall successfully isolated and cultured this bacterium from a gastric mucosal biopsy sample, and confirmed that this bacterium was the culprit of gastritis (Marshell et al., Le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/357A61P1/04A61P35/00
Inventor 朱永宏周水平陈建明马晓慧李欣欣栗志文张兰兰王方宇张悦
Owner TIANJIN TASLY PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com